MAZZANTI, ANDREA
 Distribuzione geografica
Continente #
EU - Europa 4.564
NA - Nord America 2.250
AS - Asia 1.825
SA - Sud America 235
AF - Africa 35
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.919
Nazione #
IT - Italia 3.196
US - Stati Uniti d'America 2.201
CN - Cina 1.005
IE - Irlanda 497
SG - Singapore 365
HK - Hong Kong 249
RU - Federazione Russa 248
BR - Brasile 199
NL - Olanda 140
DE - Germania 127
FI - Finlandia 117
VN - Vietnam 69
GB - Regno Unito 51
CA - Canada 33
FR - Francia 28
SE - Svezia 28
PL - Polonia 26
UA - Ucraina 26
IN - India 24
JP - Giappone 21
AR - Argentina 19
ZA - Sudafrica 19
AT - Austria 17
BD - Bangladesh 16
MX - Messico 14
TR - Turchia 14
IR - Iran 11
ES - Italia 10
BE - Belgio 9
CH - Svizzera 7
ID - Indonesia 7
CZ - Repubblica Ceca 6
LT - Lituania 6
AE - Emirati Arabi Uniti 5
EC - Ecuador 5
AU - Australia 4
JO - Giordania 4
PE - Perù 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AM - Armenia 3
CO - Colombia 3
GR - Grecia 3
IL - Israele 3
IQ - Iraq 3
LV - Lettonia 3
MA - Marocco 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
TN - Tunisia 3
AZ - Azerbaigian 2
BG - Bulgaria 2
GE - Georgia 2
HU - Ungheria 2
KE - Kenya 2
KW - Kuwait 2
KZ - Kazakistan 2
MU - Mauritius 2
NP - Nepal 2
PK - Pakistan 2
PS - Palestinian Territory 2
PT - Portogallo 2
SM - San Marino 2
UY - Uruguay 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CL - Cile 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
EE - Estonia 1
EG - Egitto 1
EU - Europa 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
MW - Malawi 1
NG - Nigeria 1
PH - Filippine 1
PY - Paraguay 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.919
Città #
Dublin 495
Chandler 373
Milan 344
Beijing 246
Hong Kong 246
Dallas 232
Rome 220
Ashburn 191
Nanjing 140
Boardman 118
Naples 116
Singapore 112
Shanghai 89
Helsinki 74
Princeton 74
San Genesio Ed Uniti 74
Turin 74
Jacksonville 70
Lawrence 70
Los Angeles 60
Medford 59
Moscow 58
Florence 56
Wilmington 56
Changsha 55
New York 52
Nanchang 51
Bari 47
Jiaxing 46
Hebei 44
Shenyang 43
Palermo 41
Bologna 40
Redondo Beach 39
Tianjin 38
Munich 34
Genoa 32
Buffalo 30
Parma 29
Catania 28
Hangzhou 27
Cagliari 25
Ann Arbor 24
Brescia 22
Ho Chi Minh City 21
The Dalles 20
Padova 19
Chicago 18
Hanoi 18
Pavia 18
São Paulo 18
Warsaw 18
Verona 17
Woodbridge 17
Livorno 16
Norwalk 16
Turku 16
Nuremberg 15
Pescara 15
Johannesburg 14
Toronto 14
Brooklyn 13
London 13
Messina 13
Seattle 13
Tokyo 13
Imola 12
Pisa 12
Monserrato 11
San Francisco 11
Montreal 10
Pomigliano d'Arco 10
Taranto 10
Trieste 10
Brussels 9
Modena 9
Reggio Emilia 9
Venice 9
Falls Church 8
Reggio Calabria 8
Santa Clara 8
Vienna 8
Baranzate 7
Belo Horizonte 7
Chennai 7
Columbus 7
Spotorno 7
Stockholm 7
Zhengzhou 7
Ancona 6
Apiro 6
Banjara Hills 6
Bergamo 6
Catanzaro 6
Denver 6
Fairfield 6
Falkenstein 6
Frankfurt am Main 6
Guangzhou 6
Haiphong 6
Totale 5.018
Nome #
Sindrome di Brugada e idoneità alla mansione: case report 3.251
From decision to shared-decision: Introducing patients' preferences into clinical decision analysis. 165
Graphical Representation of Life Paths to Better Convey Results of Decision Models to Patients. 122
UceWeb: a Web-based Collaborative Tool for Collecting and Sharing Quality of Life Data. 114
[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology] 109
Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk 104
Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (RYR2). 100
Genetic causes of sudden cardiac death in the young. 99
Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome 99
Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome 99
[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death] 96
Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1 95
Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3 94
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) 92
Big Data as a Driver for Clinical Decision Support Systems: A Learning Health Systems Perspective 92
2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death 91
Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19 91
Clinical presentation and outcome of Brugada syndrome diagnosed with the new 2013 criteria 90
Efficacy and Limitations of Quinidine in Patients with Brugada Syndrome 88
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). 87
CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases 82
The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases 78
Brugada Syndrome: The Endless Conundrum 78
Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome 78
An International Multi-Center Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. 78
Arrhythmogenic right ventricular cardiomyopathy: Evaluation of the current diagnostic criteria and differential diagnosis 77
Programmed ventricular stimulation for risk stratification in the Brugada syndrome: A pooled analysis 76
The genetics of Long QT Syndrome 75
Gquest: Modeling patient questionnaires and administering them through a mobile platform application 72
"Ten Commandments" of 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death 68
Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk) 67
Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: JACC Focus Seminar 5/5 67
Desmoplakin cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy: two distinct forms of cardiomyopathy? 66
Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation: Personalized Medicine for Long QT Syndrome 65
Reply: Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3 64
Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome 64
Molecular Autopsy for Sudden Unexplained Death? Time to Discuss Pros and Cons. 62
Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers 62
Author Correction: Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility (Nature Genetics, (2022), 54, 3, (232-239), 10.1038/s41588-021-01007-6) 61
Assessment of absolute risk of life-threatening cardiac events in long QT syndrome patients 61
Usefulness of exercise test in the diagnosis of short QT syndrome 61
Arrhythmic Mitral Valve Prolapse: Introducing an Era of Multimodality Imaging-Based Diagnosis and Risk Stratification. 60
Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia 59
Genetic risk stratification in cardiac arrhythmias 59
Identification of a SCN5A founder mutation causing sudden death, Brugada syndrome, and conduction blocks in Southern Italy 59
An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia 58
Regulatory Light Chain (MYL2) Mutations in Familial Hypertrophic Cardiomyopathy 57
Programmed Electrophysiological Stimulation for Risk Prediction in Patients with Brugada Syndrome: Closing Time?,La estimulacion electrica programada para la prediccion del riesgo en pacientes con sindrome de Brugada: ?tiempo de cierre? 55
Brugada syndrome and job fitness: report of three cases 55
Indications for genetic testing in athletes and its indication in clinical practice 55
Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain 55
Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator 55
Brugada syndrome and job fitness: report of three cases 54
The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome 54
Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the CACNA1 Gene Associated With Brugada Syndrome 53
Value of 3D echocardiography in the diagnosis of arrhythmogenic right ventricular cardiomyopathy 52
Is there a role for genetics in the prevention of sudden cardiac death? 52
Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy 52
Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls 52
Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment-Authors' reply 52
Diagnosis of Long QT Syndrome: Time to Stand Up! 51
Novel insights in the natural history of Short QT Syndrome 50
Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome 50
Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome 50
Inherited arrhythmias: LQTS/SQTS/CPVT 49
Repeat adverse events long after percutaneous coronary revascularization in diabetics 49
Benefit of Implantable Cardioverter-Defibrillators in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia - Reply 47
Genetic Arrhythmias (Channelopathies) 47
Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome 47
Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. 46
Dilated cardiomyopathy 46
Nonmodifiable Risk Factors Predict Outcomes in Brugada Syndrome 45
Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population 45
Los estudios genéticos en la prevención de la muerte súbita: ¿realidad o ficción? 45
Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility 45
Transmural APD heterogeneity determines ventricular arrhythmogenesis in LQT8 syndrome: Insights from Bidomain computational modeling 41
Unexpected impairment of INa current underpins reentrant arrhythmias in a knock-in swine model of Timothy syndrome 41
The new kids on the block of arrhythmogenic disorders: Short QT syndrome and early repolarization 41
Long-term follow-up of patients with short QT syndrome 41
Risk Stratification in the Long QT Syndrome 40
Personalized therapies for cardiac channelopathies 39
Programmed electrophysiological stimulation for risk prediction in patients with Brugada syndrome: closing time? 39
Genotype-Phenotype Correlation of SCN5A Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands 38
Short QT syndromes 37
Prevention of Sudden Death and Management of Ventricular Arrhythmias in Arrhythmogenic Cardiomyopathy 35
The interpretation of genetic tests in inherited cardiovascular diseases 35
Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients 34
Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers 33
Role of CACNA1C in Brugada syndrome: Prevalence and phenotype of probands referred for genetic testing 33
Warning: Not All Carriers of Pathogenic Mutations in Desmosomal Genes Should Follow the Same Medical Advices! 33
Characteristics of Patients with Spontaneous Versus Drug-Induced Brugada Electrocardiogram: Sub-Analysis From the SABRUS 32
Characterization of Skeletal Muscle Biopsy and Derived Myoblasts in a Patient Carrying Arg14del Mutation in Phospholamban Gene 31
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome 27
Induction of ventricular fibrillation during programmed ventricular stimulation in a patient with CASQ2 heterozygous mutation 17
Totale 9.067
Categoria #
all - tutte 33.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.080


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021149 0 0 0 0 0 17 6 39 58 17 9 3
2021/2022321 0 7 14 0 7 13 3 19 15 24 46 173
2022/20231.174 146 92 19 69 86 101 0 54 564 3 25 15
2023/20241.841 62 86 94 175 182 257 199 168 67 177 162 212
2024/20252.950 276 188 154 197 145 229 225 262 524 168 222 360
2025/20261.772 364 239 456 430 283 0 0 0 0 0 0 0
Totale 9.067